Consun Pharmaceutical Group Ltd
Company Profile
Business description
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Contact
71, Dongpeng Avenue
Eastern section
Guangzhou Economic and Technological Development
Guangzhou
CHNT: +86 2082264529
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
3,073
Stocks News & Analysis
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,375.90 | 19.70 | 0.21% |
| CAC 40 | 8,139.20 | 62.20 | 0.77% |
| DAX 40 | 24,152.14 | 29.23 | -0.12% |
| Dow JONES (US) | 46,340.54 | 87.23 | 0.19% |
| FTSE 100 | 9,396.86 | 27.89 | -0.30% |
| HKSE | 25,888.51 | 22.09 | -0.09% |
| NASDAQ | 22,789.64 | 119.56 | 0.53% |
| Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
| NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
| S&P 500 | 6,689.00 | 17.94 | 0.27% |
| S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
| SSE Composite Index | 3,916.23 | 4.02 | 0.10% |